Abstract:

Objective   To observe whether lansoprazole can alleviate the discomfort of gastrointestinal symptoms caused by metformin and investigate the effects of lansoprazole on the blood glucose, gastrin and potential mechanism in the type 2 diabetes mellitus. Methods   Fifty-one patients with T2DM were enrolled and divided into the lansoprazole group (n=26) and control group (n=25). We measured the levels of indicators such as fasting blood glucose(FBG), glycosylated hemoglobin(HbA1C), gastrin, fasting insulin(FINS), lipid, hepatic and renal function, and serum uric acid(UA) before and after treatment. Results   Lansoprazole could alleviate the discomfort of gastrointestinal symptoms which caused by metformin, and the effective remission rate was 95.0%. After (3.05±1.07) days, the symptoms were fully remitted. The levels of the gastrin were significantly increased in the lansoprazole group ［(158.26±11.85) vs (95.61±4.48)ng/L, P＜0.05］. The levels of the FBG ［(7.22±0.45) vs (7.70±0.29)mmol/L, P＜0.05)］ and HbA1C ［(7.28±0.76)% vs (7.85±0.05)%, P＜0.05］ in the lansoprazole groups were significantly declined in comparison with the control group after treatment. The changes of FBG (1.16±0.62 vs 0.51±0.45, P＜0.05) and HbA1C in the lansoprazole group (0.64±0.50 vs 0.33±0.43，P＜0.05) were significantly different in comparison with the control group(P＜0.05). Correlation regression analysis showed that the decrease of HbA1C was associated with the gastrin rising (r=-0.605, P＜0.05). Conclusion   Lansoprazole can alleviate the discomfort of gastrointestinal symptoms caused by metformin and reduce the blood glucose levels in T2DM patients, which may be related with the increase of gastrin.

Key words: Proton pump inhibitor; Type 2 diabetes mellitus; Glycosylated hemoglobin; Metformin; Gastrin